FDA fast track designation granted for EOquin for bladder cancer

Spectrum Pharmaceuticals and Allergan announced that the FDA has granted fast track designation to EOquin (apaziquone) for the treatment of non-muscle invasive bladder cancer, a form of bladder cancer localized in the surface layers of the bladder that has not spread to the deeper muscle layer. In a marker lesion study, where patients had previously failed multiple therapies, apaziquone produced a 67% complete response and was well-tolerated. Spectrum is continuing to investigate the efficacy and safety of EOquin in Phase 3 studies.  

EOquin is a quinone based bioreductive prodrug activated by reductive enzymes produced by bladder tumor cells, to form a cytotoxic alkylating agent.

For more information call (877) 387-4538 or visit www.spectrumpharm.com.